These innovative agents represent a significant leap in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://aadamjyqv539376.blog2freedom.com/39213064/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide